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ABSTRACT
Background: The health consequences of lactose intolerance (LI) are unclear.
Aims: To investigate the effects of LI on stature and vitamin D status.
Hypotheses: LI subjects will have similar heights and vitamin D status as controls.
Subjects and Methods: Prepubertal children of ages 3-12 years with LI (n=38, age 8.61 ± 3.08y, male/female
19/19) were compared to healthy, age- and gender-matched controls (n=49, age 7.95±2.64, male/female 28/21).
Inclusion criteria: prepubertal status (boys: testicular volume <3cc; girls: Tanner 1 breasts), diagnosis of LI by
hydrogen breath test, and no history of calcium or vitamin D supplementation. Vitamin D deficiency was defined as
25-hydroxyvitamin D [25(OH)D] <50 nmol/L. Gender-adjusted midparental target height (MPTH) z-score was
calculated using NCHS data for 18 year-old adults. Data were expressed as mean ± SD.
Results: There was no significant difference in 25(OH)D between the LI and non-LI subjects (60.1±21.1, vs. 65.4 ±
26.1 nmol/L, p = 0.29). Upon stratification into normal weight (BMI <85th percentile) vs. overweight/obese (BMI ≥85th
percentile), the normal weight controls had significantly higher 25(OH)D level than both the normal weight LI children
(78.3 ± 32.6 vs. 62.9 ± 23.2, p = 0.025), and the overweight/obese LI children (78.3±32.6 vs. 55.3±16.5, p = 0.004).
Secondly, there was no overall difference in height z-score between the LI children and controls. The normal weight
LI patients had similar height as normal controls (-0.46 ± 0.89 vs. -0.71 ± 1.67, p = 0.53), while the overweight/obese
LI group was taller than the normal weight controls (0.36 ± 1.41 vs. -0.71 ± 1.67, p = 0.049), and of similar height as
the overweight/obese controls (0.36 ± 1.41 vs. 0.87 ± 1.45, p = 0.28). MPTH z-score was similar between the groups.
Conclusion: Short stature and vitamin D deficiency are not features of LI in prepubertal children.
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Introduction
There is no consensus on the health consequences of
lactose intolerance (LI)[1,2]. The commonest form of LI,
primary LI, results from either a genetic inability to produce
lactase, an enzyme that breaks down lactose to glucose and
galactose, or from an age-related down-regulation of lactase
production[3]. Bacterial fermentation of the non-digested
lactose leads to the production of short chain fatty acids and
gas including hydrogen, carbon dioxide, and methane[4]. The
degree of elevation of these gases as measured by the
hydrogen breath test forms the basis of the clinical diagnosis of
LI[4]. The associated bloating, diarrhea, and abdominal pain
lead to the avoidance of dairy products[5]. A central hypothesis
in LI is that dairy avoidance leads to reduced intake of protein
and calcium, which consequently results in poor growth, short
stature and low bone mineral density, respectively [6].
However, no systematic study has been conducted in
prepubertal children to accurately assess this hypothesis.
Even though the studies that demonstrated an association
between LI and low bone mineral density have provided
important information in this field [6-8], they failed to articulate a
coherent biochemical basis for the reported low bone mineral
density and increased fracture risk in their cohorts as they
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provided no data on the vitamin D status of these lactose
intolerant children and their control groups. It is unclear
whether the bone findings from the above referenced studies
were due to insufficient calcium intake alone, or whether there
was an added effect from vitamin D deficiency as a result of
reduced intake of vitamin D-fortified dairy products. This is
crucial because calcium absorption in the gastrointestinal tract
depends on vitamin D-mediated processes. Therefore, a
coherent hypothesis on low bone mineral density in LI should
take into consideration the primary role of vitamin D in calcium
absorption. Our research question was whether prepubertal
children with LI had significantly lower vitamin D levels
compared to their age and gender-matched peers.
Another controversial area in LI research is whether this
condition is associated with short stature. Although some
investigators have suggested that adequate calcium intake
during the growth period may be critical for reaching optimal
bone growth during the growing years[9], others have provided
evidence of short stature in children with LI, milk allergy, or
those on milk-elimination diets[10-12]. Further studies in
prepubertal children showed that long term avoidance of cow’s
milk was associated with small stature and diminished bone
health[6,10]. Even though several studies have shown positive
associations between milk intake and height in prepubertal
children[13-16], others have shown no such
relationships[17,18]. A recent analysis reports that the
biological sequalae of routine milk consumption, such as
statural growth, are not well understood[19]. Even though the
circulating levels of the growth promoting peptide, insulin-like
growth factor-I (IGF-I), rises after milk consumption[20], it is
unclear whether the rise in IGF-I levels is due to the IGF-I
contained in milk or as a result of endogenous IGF-I
production[20]. More importantly, because elevated serum IGF-
I levels limit growth hormone production via a negative
feedback mechanism[21,22], the net effect of milk-associated
IGF-I elevation on stature in prepubertal children is unclear.
Because of the lack of a well-designed study on the effect of
LI on stature and vitamin D metabolism, gastroenterologists are
unable to provide the much needed prognostic information on
bone health and stature to parents and guardians of children
with newly-diagnosed LI.
This study was designed to address these two important
questions and provide the needed data on height and vitamin D
status of these children. The primary aim of this study was to
compare the vitamin D status of prepubertal children with LI to
non-affected children of similar age, gender, and prepubertal
status. The study’s primary hypothesis was that children with LI
would have similar vitamin D status as their healthy peers. The
second aim of the study was to investigate whether prepubertal
children with LI were significantly shorter than their healthy
peers. The study’s secondary hypothesis was that children with
LI would be of similar height as their healthy peers.
To test these hypotheses, a two-site cross-sectional study
was conducted in prepubertal children with a diagnosis of LI
who also had a 25(OH)D level measured. These results were
compared to a cohort of healthy prepubertal children who
participated in a prospective cross-sectional study on the role
of vitamin D metabolism on bone mineral content (clinical trial
identifier NCT00756899).
Subjects and Methods
The study protocol was approved by the Institutional Review
Boards of the University of Massachusetts and the Saint
Vincent Hospital, Worcester, Massachusetts. The control group
(n=49) was drawn from a study to evaluate the role of vitamin D
status on bone mineral density. Its clinical trial identification
number is NCT00756899. Written informed consent was
obtained from each subject’s parent or legal guardian and
assent was obtained from each subject prior to participating in
the study. The study group (n=38) consisted of prepubertal
children of ages 3-12 years who were diagnosed with LI at the
Saint Vincent Hospital and the UMassMemorial Medical Center
between 2008 and 2012.
Subjects
The control group consisted of healthy children who were
recruited by means of advertisement using paper flyers
distributed to the primary care physician offices in Central New
England, USA. Fifty subjects signed consent for the study.
Forty-nine subjects (28 males and 21 females) between 3-12
years of age were studied. The mean age of the cohort was
7.95 ± 2.63 years; mean age of females 7.09 ± 2.37; mean age
of males 8.59 ± 2.68 years. All participants were of prepubertal
status: males, with testicular volume of ≤ 3 cc, and females
with Tanner Stage 1 breasts as determined by palpation by the
principal investigator. Subjects were excluded if they had any
known metabolic or genetic diseases resulting in obesity such
as severe hypothyroidism, pseudohypoparathyroidism, or
Cushing’s syndrome. We also excluded patients with systemic
illnesses such as diabetes mellitus, nephrotic syndrome,
chronic renal disease, or chronic inflammatory disorders.
Subjects with a history of significant weight loss or gain
(change of >10% body weight in 6 months) were excluded from
the study. Methods used for exclusion included history,
physical examination, and screening laboratory tests for fasting
blood glucose, cortisol, urinalysis, comprehensive metabolic
panel, serum creatinine, and thyroid function tests.
Subjects were included in the study group if they had a
diagnosis of LI confirmed by hydrogen breath test. All study
subjects were prepubertal, and had no history of secondary
causes of LI such as celiac disease, infectious enteritis, and
Crohn’s disease. A further inclusion criterion was the
availability of 25(OH)D level measured at the time diagnosis of
LI. The estimation of 25(OH)D at the time of diagnosis is a
routine practice at both centers. Patients were excluded if they
had diseases of calcium metabolism or vitamin D metabolism,
and were receiving calcium, vitamin D or multivitamin
supplementation. Seven eligible patients were excluded
because they were receiving vitamin D supplements prior to
the hydrogen breath test.
Lactose Intolerance: Vitamin D Status and Stature
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Study Methods
Participants in both the study group and control group were
evaluated between 0800-1100 hours following an overnight
fast.
Anthropometry.  Height was measured to the nearest 0.1
cm using a wall-mounted stadiometer (Holtain Ltd, Crymych,
Dyfed, UK) that was calibrated daily. Weight was measured to
the nearest 0.1 kg using an upright scale. BMI was derived
using the formula weight/height2 (kg/m2), and expressed as z-
score for age and gender based on National Center for Health
Statistics (NCHS) data [23]. Gender-adjusted mid-parental
target height (MPTH) z-score was calculated for 18 year old
adults using NCHS data and the standard formula for
MPTH[24]. The MPTH is a child's projected adult height based
on the heights of his or her parents and is calculated as
follows: for girls, the father's height minus 13 cm (5 in) is
averaged with the mother's height; for boys, the mother's
height plus 13 cm is averaged with the father's height[24].
Anthropometric data were expressed as mean ± SD. Heights of
parents were obtained by history[25] and some by
measurement in the clinic. Bone mineral density was not
measured because of funding constraints.
Hydrogen Breath Test: Lactest by Quintron[26] (orange-
flavored lactose).  Prior to the testing, all patients were
instructed not to take any form of antibiotics 10 days prior to
the day of testing; not to ingest a high fiber diet one week prior
to the test; and not to smoke, brush their teeth, or take any
medications on the morning of the test; and to fast overnight for
the test. All patients ingested Lactose at a dose of 1 g/kg body
weight up to 25 grams dissolved in 8 ounces of water. Breaths
were sampled at baseline 0, 30, 60, 90, and 120 minutes or
until hydrogen/methane (H2/CH4) ppm reached 20/12 over the
lowest preceding measures. Positive results were defined by
the following criteria: (a) breath H2 level increase of at least 20
ppm over the lowest preceding value within the test period; (b)
breath CH4 level increase of at least 12 ppm over the baseline
within the test period; (c) combined increase of at least 15 ppm
within the test period.
Biochemical Study.  A single venous blood sample was
collected for serum 25(OH)D estimation between 0800 and
0900 hours.
Assay.  Serum levels of 25(OH)D were analyzed using 25-
hydroxy chemiluminescent immunoassay (DiaSorin Liaison;
Stillwater, Minnesota), which has a 100% cross-reactivity with
both metabolites of 25(OH)D namely, 25(OH)D2 and 25(OH)D3
and thus measures total serum 25(OH)D content. Its functional
sensitivity is 10 nmol/L (4 ng/mL), and its intra- and inter-assay
coefficients of variation are 5% and 8.2% respectively. Vitamin
D status was classified according to American Academy of
Pediatrics and the Institutes of Medicine criteria as deficient,
25(OH)D <50 nmol/L (<20 ng/mL); or sufficient, 25(OH)D >50
nmol/L (>20 ng/mL)[27]. Because vitamin D status could vary
with sunlight exposure and the seasons, we categorized each
subject’s visit according to the seasons as follows: fall
(September 22 – December 21), winter (December 22- March
21), spring (March 22 – June 21), and summer (June 22-
September 21)[28].
Statistical Analyses
Statistical analyses were performed using SPSS v. 21 (IBM
Corporation, Somers, NY).
Normal probability plots were constructed with the variables
of interest. No departure from normality was detected, allowing
for the use of parametric tests, without the need for
transformation. Means, standard deviations and percentages
were calculated for descriptive summary statistics. Proportions
were compared using Fisher’s exact test. To adjust for the
influence of adiposity on both height and 25(OH)D levels,
subjects were stratified into normal weight vs. overweight/
obese groups. The rationale for this stratification is because
obesity is associated with vitamin D deficiency, as vitamin D is
subject to either sequestration[29] or volumetric dilution[30] in
fat depots. Equally, overweight/obese children are generally
taller than their normal weight peers[31,32]. Overweight was
defined as BMI of ≥85th but <95th percentile, while obesity was
defined as a BMI of > 95th percentile for age and sex.
Differences between the four subgroups (normal weight vs.
overweight/obese controls and study subjects) were first
explored using a two-way ANOVA [F (3,86) = 4.731, p = 0.004],
followed by post-hoc comparisons. Data were expressed as
mean ± standard deviation (SD).
Results
Table 1 shows the mean (±SD) values for age, gender,
seasonality, anthropometric, and biochemical parameters of
the LI subjects and normal controls. The control subjects had
significantly higher weight and BMI z-score compared to the LI
children. There were no significant differences in height z-
score, MPTH z-score, or 25(OH)D level between the subjects
and controls.
25: hydroxyvitmin D
The normal weight controls had significantly higher 25(OH)D
levels than the normal weight LI children (78.3 ± 32.6 vs. 62.9 ±
23.2 nmol/L, p=0.025), and much greater levels than the
Table 1. Comparative Analysis of the Characteristics of
Children with Lactose Intolerance and Controls.
Parameters Lactose Intolerant n=38 Controls n=49 p
Age (years) 8.62 ± 3.08 7.95 ± 2.63 0.29
Sex (% males) 50.00 57.14 0.51
Race (% white) 73.7 85.7 0.18
Height SDS -0.16 ± 1.16 0.19 ± 1.71 0.27
Weight SDS 0.32 ± 1.38 1.05 ± 1.97 0.045
BMI SDS 0.56 ± 1.37 1.26 ± 1.62 0.031
MPTH SDS 0.0014 ± 1.31 (n=14) 0.025 ± 0.95 (n=26) 0.10
25(OH)D (nmol/L) 60.1 ± 21.1 65.4 ± 26.1 0.29
Season (% Summer-Fall) 47.37 34.69 0.23
SDS = standard deviation score; MPTH = mid-parental target height; 25(OH)D=
25-hydroxyvitamin D; BMI = body mass index
doi: 10.1371/journal.pone.0078653.t001
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overweight/obese LI children (78.3 ± 32.6 vs. 55.3 ± 16.5
nmol/L, p =0.004) (Figure 1). There was neither a difference in
25(OH)D level between the overweight/obese control subjects
and overweight obese LI children (55.7 ± 13.9 vs. 55.3 ± 16.5
nmol/L, p=0.95), nor between the overweight/obese controls
and normal weight LI children (55.7 ± 14.0 vs. 62.9 ± 23.2
nmol/L, p=0.26). Even though there was a significant difference
between normal weight control and overweight/obese controls
(78.3 ± 32.6 vs. 55.7 ± 13.9 nmol/L, p=0.001), there was no
difference in 25(OH)D level between the normal weight LI and
overweight/obese LI (62.9 ± 23.2 vs. 55.3 ± 16.5 nmol/L,
p=0.32).
An analysis of the racial/ethnic composition of the LI subjects
and controls showed that both the LI subjects and controls
were predominantly white. There were no significant
differences in height and 25(OH)D levels among the racial/
ethnic groups (Table 2). Equally, there were no significant
differences in serum 25(OH)D levels across the seasons when
the racial/ethnic groups were analyzed individually (Table 3).
Height z-score
Although there were no differences in height z-score nor
MPTH z-score when all the LI children were compared to the
normal controls (Table 1), there were differences when the two
groups were subdivided into normal weight (BMI <85th
percentile) vs. overweight/obese (BMI ≥85th percentile) (Figure
2).The normal weight LI patients were of similar height as
normal weight controls (-0.46 ± 0.89 vs. -0.71 ± 1.67, p = 0.53),
but were significantly shorter than the overweight/ obese
controls (-0.46 ± 0.89 vs. 0.90 ± 1.45, p <0.001), and nearly so
for the obese LI patients (-0.46 ± 0.89 vs. 0.36 ± 1.41, p =
0.067). Interestingly, the overweight/obese LI group was taller
than the normal weight controls (0.36 ± 1.41 vs. -0.71 ± 1.67, p
= 0.049), and of similar height as the overweight/obese controls
(0.36 ± 1.41 vs. 0.90 ± 1.45, p = 0.28).
Figure 1.  Box plots of the comparison of 25-hydroxyvitamin D values of patients with lactose intolerance and normal
controls stratified by body mass index.  This figure shows that the overweight/obese controls and overweight/obese lactose
intolerant children had lower vitamin D levels compared to their respective normal weight peers. Note: 50 nmol/L=20 ng/mL.
doi: 10.1371/journal.pone.0078653.g001
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There was no statistically significant relationship between
height z-score and serum concentration of 25(OH)D in all
subjects after adjusting for age, race, season, and BMI z-score
(β = 0.070, p = 0.562, R2 = 0.139) (Figure 3).
Discussion
This study showed no significant difference in the serum
concentration of 25(OH)D between children with LI and their
normal controls. However, when adjusted for BMI, both the
normal weight LI- and overweight/obese LI patients had similar
serum concentrations of 25(OH)D to the overweight/obese
controls, but significantly lower 25(OH)D levels than the normal
weight controls. Furthermore, children with LI had significantly
reduced values for weight and BMI z-score, but no difference in
height z-score or MPTH z-score compared to controls. There
was no relationship between height z-score and serum
concentration of 25(OH)D in all subjects.
Table 2. Comparative Analysis of the Racial/Ethnic
Composition of the Participants with respect to Height z-
score and 25-hydroxyitamin D levels.
Parameters Lactose Intolerant Controls
 Whites Blacks *Others p Whites Blacks *Others p
N 29(76.3%)
6
(15.8%)
3
(7.9%) 0.72
45
(91.8%)
2
(4.1%)
2
(4.1%) 0.50
Height z-
score
-0.12
±1.16
-0.05
±1.47
-0.69 ±
0.63 0.71
0.21 ±
1.72
1.08 ±
0.12
-1.17 ±
2.55 0.42
25(OH)D
(nmol/L)
63.2 ±
21.1
48.9 ±
13.7
51.9 ±
30.2 0.26
66.7 ±
26.8
46.2 ±
8.8
56.2 ±
1.8 0.50
*Others: Asians, Multi-racial, Pacific Islanders; 25(OH)D 25-hydroxyvitamin D
doi: 10.1371/journal.pone.0078653.t002
Table 3. A Comparative Analysis of the 25-hydroxyvitamin
D levels in nmol/L Stratified by Race and Season.
Season
 Lactose intolerant Controls
Race SummerFall Winter Springp SummerFall WinterSpringp
White n = 6 n=8 n=10 n=5  n=9 n=8 n=10 n=18  
25(OH)D
(nmol/L)
72.1 ±
18.8
70.9
±
20.0
52.9
±
21.8
60.8
±
20.2
0.21 84.03± 27.0
62.1
±
18.3
53.9
±
15.7
67.1
±
31.3
0.09
Black n=0 n=2 n=3 n=1  n=0 n=0 n=0 n=2 -
25(OH)D
(nmol/L) -
63.3
±
1.6
38.9
±
10.6
50.4 0.12 - - - 46.2± 8.8  
*Others n=1 n=0 n=2 n=0  n=0 n=0 n=0 n=2 -
25(OH)D
(nmol/L) 78.9  
37.9
±
25.4
- 0.41 - - - 56.2± 1.8 -
*Others: Asians, Multi-racial, Pacific Islanders; 25(OH)D 25-hydroxyvitamin D
doi: 10.1371/journal.pone.0078653.t003
The findings from this study are important when viewed in
light of the recent reports on LI from the Agency for Healthcare
Research and Quality, and the National Institutes of Health
Consensus statement which conclude that the evidence
regarding the effect of dairy exclusion diets on long term
gastrointestinal and bone health outcomes is relatively sparse
in quantity and of low quality[1,2]. Available data do not
strongly indicate that dairy-free diets are independently
associated with poor long-term bone health outcomes[2]. This
study’s finding of normal vitamin D status in these subjects may
partially explain the absence of diminished long-term bone
health outcomes in the reports cited above.
Though some studies have reported an association between
calcium intake and bone mineral content (BMC) and BMD in
children with LI or cow’s milk allergy[6,8,33], other investigators
found no such associations[10,34] in carefully-designed studies
that matched the experimental groups’ intake of calcium, milk-
derived calcium, milk, cheese, yogurt, ice cream, and calcium
density of the diet. The studies that reported associations
between calcium intake and BMD did not evaluate the subjects’
vitamin D status[6,8,33]. Therefore, it is unclear whether the
low BMD described in these studies was due to hypocalcemia
secondary to poor calcium intake, or poor calcium absorption
as a result of vitamin D deficiency.
25: hydroxyvitamin D
This current study did not detect vitamin D deficiency,
marked by serum 25(OH)D of <50 nmol/L, in our cohort with LI.
This is not surprising as oral intake is not the only source of
vitamin D, as this prohormone is synthesized in the skin
through exposure to ultra-violet radiation. Hence, dietary intake
of vitamin D is not necessarily required to maintain normal
vitamin D status in individuals who maintain adequate
exposure to sunlight. Vitamin D is also found in some foods,
such as fish oil, egg yolk, fortified margarine, and breakfast
cereals[35] which are available to most patients with LI.
We, however, showed that overweight/obese children had
lower serum concentrations of 25(OH)D compared to the
normal weight peers. This is consistent with other reports
showing that increased adiposity is associated with vitamin D
deficiency [36]. The mechanism of this association is unclear,
however, proposed causative factors include: poor nutrition,
inadequate exposure to sunlight, and the sequestration[29] and
or volumetric dilution[30] of vitamin D in fat stores in
overweight/obese individuals. Therefore, it is possible that
overweight/obese subjects with LI may require a higher dose of
vitamin D to maintain normal serum concentrations of 25(OH)D
as the fat soluble, non-hydroxylated vitamin D is mainly stored
in adipose tissue leading to reduced bioavailability[37].
Height z-score
We did not detect a significant difference in height z-score
between LI children and their unaffected peers in the initial
analysis. However, when the subjects were stratified into
normal weight vs. overweight/obese, the LI patients with BMI
>85th percentile were taller than the normal weight controls
(BMI <85th percentile), and nearly significantly taller than the
normal weight LI subjects. The overweight/obese controls were
Lactose Intolerance: Vitamin D Status and Stature
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not significantly taller than the overweight/obese LI subjects,
but were significantly taller than the normal weight LI subjects.
Similar associations between height and adiposity in children
have been reported in several regions of the world in studies
carried out in the United States[31,38,39], Australia[32], and
Japan[40]. The reason for the differential tall stature in
overweight/obese prepubertal children is not fully known, but
suggested mechanisms include: insulin stimulation of both the
insulin receptor and the insulin-like factor-I receptor[41], the
stimulatory effects of leptin on the hypothalamic-pituitary-
gonadal axis[42-44], skeletal growth centers[45], and the
activity of enzymes essential for the synthesis of adrenal
androgens[46].
A number of studies have reported that children with LI are
shorter than their unaffected peers[6,10-12], however, the
study by Isolauri et al[12] did not adjust for the physiologic
catch-up or catch-down growth that is noted in normal infants
and children in the first 18 months of life as they adjust their
pattern of growth away from the intrauterine environment to
their genetic growth potential[47]. The studies in older children
did not adjust for MPTH (genetic potential)[6,11]. Furthermore,
Paganus et al[11] did not detect any association between
dietary intake and nutritional status in children with cow’s milk
allergy while a 21-year longitudinal Finnish study found no
association between a specific genotype of LI and mean
growth velocity or final mean adult height for either boys or
girls[48].
Our approach to the determination of height differential
between LI subjects and normal controls differed from earlier
studies. Robust methodologies, such as expressing the
subjects’ heights in z-score, ensured that each measurement
was adjusted for age and gender. Furthermore, adjusting the
height data for mid-parental height z-score ensured that
genetic short stature was not a confounder in the analysis for
height outcome. Finally, patients with syndromes associated
short stature, for example Down syndrome, were all excluded
Figure 2.  Box plots of the comparison of height standard deviation scores of patients with lactose intolerance and normal
controls stratified by body mass index.  This figure shows that the overweight/obese children with lactose intolerance were taller
than the normal weight controls but of similar height as the overweight/obese controls.
doi: 10.1371/journal.pone.0078653.g002
Lactose Intolerance: Vitamin D Status and Stature
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from this study. The previous studies that investigated height
differences in either LI subjects or cow’s milk avoiders did not
account for all of these confounders.
This study has some limitations. First, the cross-sectional
study design limited causal inference about the effects of
adiposity on vitamin D or stature in LI. The relatively small
sample size could have precluded the detection of subtle
differences between the groups. We did not collect dietary
data, such as calcium intake, on the patients as some children
with LI may in fact be consuming lactose-reduced milk, milk
alternatives, or dairy products with reduced lactose content.
We also did not have data on parathyroid hormone levels
which could be elevated in states of vitamin D deficiency and
hypocalcemia. Bone age data were not available for our cohort.
It is possible that adiposity could lead to bone age
advancement and possibly contribute to the height differential
between normal weight and overweight/obese children.
However, this is less likely in a cohort of prepubertal children.
The unique strength of this study is that it was conducted
exclusively in prepubertal children. Studies in prepubertal
children are a better guide to potential causal associations than
studies in pubertal or postpubertal subjects because
associations in childhood are less prone to confounding
physiologic and lifestyle factors, such as the different stages
pubertal maturation, and the effects of fluctuations in pubertal
hormone levels on growth and adiposity. This prepubertal
cohort represents the youngest group of subjects in whom the
association between adiposity and height in LI could be
demonstrated. The robust group of healthy prepubertal children
in the control group ensured the validity of the anthropometric
and biochemical comparisons. Furthermore, the height data
were expressed in standard deviation scores, thereby adjusting
Figure 3.  The relationship between height z-score and serum 25-hydroxyvitamin D concentration.  This figure shows no
relationship between height z-score and serum concentration of 25(OH)D in all subjects after adjusting for age, race, season, and
BMI z-score (β=0.070, p = 0.562, R2=0.139).
doi: 10.1371/journal.pone.0078653.g003
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for age and gender; and further adjusted for mid-parental target
height to exclude the effects of genetic causes of short stature.
Subjects with acquired or congenital causes of short stature
were excluded from the study.
In conclusion, we have shown that vitamin D deficiency is not
a central feature of LI in prepubertal children. However, when
adjusted for BMI status, both the normal weight and
overweight/obese patients with LI had significantly lower
25(OH)D levels compared to the normal-weight controls.
Studies examining the role of calcium on BMD in LI patients
should address the vitamin D status of the cohort. This study
also showed that prepubertal children with LI were not shorter
than normal controls. In fact, the obese LI subjects were taller
than normal weight controls, and of similar height as the
overweight/obese controls. Therefore, we conclude that LI
does not have a significant effect on the overall stature or
vitamin D status of the affected children.
Data depository
Our study data files are publicly deposited in the University of
Massachusetts Medical School’s institutional repository,
eScholarship@UMMS. The permanent link to the data is http://
escholarship.umassmed.edu/datasets/1/.
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